Influence of storage conditions and extraction methods on the quantity and quality of circulating cell-free DNA (ccfDNA): The SPIDIA-DNAplas External Quality Assessment experience

Clinical Chemistry and Laboratory Medicine

Volumn 53, Issue 12, 2015, Pages 1935-1942

  Malentacchi, Francesca ^a   Pizzamiglio, Sara ^b   Verderio, Paolo ^b   Pazzagli, Mario ^a   Orlando, Claudio ^a   Ciniselli, Chiara Maura ^b   Günther, Kalle ^c   Gelmini, Stefania ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c QIAGEN GMBH   (Germany)

Author keywords

circulating cell free DNA; External Quality Assessment; pre analytical phase

Indexed keywords

CELL DNA; CIRCULATING CELL FREE DNA; UNCLASSIFIED DRUG; DNA;

ARTICLE; CLINICAL LABORATORY; CONTROLLED STUDY; DNA EXTRACTION; HUMAN; MULTIPLEX POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITY CONTROL; STANDARDIZATION; STORAGE; STORAGE TEMPERATURE; TIME; BLOOD; BLOOD SAMPLING; BLOOD STORAGE; ISOLATION AND PURIFICATION; PROCEDURES; STANDARDS;

BLOOD PRESERVATION; BLOOD SPECIMEN COLLECTION; DNA; HUMANS; QUALITY CONTROL;

EID: 84944079398     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-1161     Document Type: Article

References (31)

1. Gahan PB, Swaminathan R. Circulating nucleic acids in plasma or serum recent developments. Ann N Y Acad Sci 2008;1137:1-6.
2. Chan KC, Lo YM. Circulating nucleic acids as a tumor marker. Histol Histopathol 2002;17:937-43.
3. van der Vaart M, Pretorius PJ. Circulating DNA. Its origin and fluctuation. Ann N Y Acad Sci 2008;1137:18-26.
4. Elshimali YI, Khaddour H, Sarkissyan M, Wu Y, Vadgama JV. The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci 2013;14:18925-58.
5. Diaz LAJ, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014;32:579-86.
6. Fleishhacker M, Schmidt B. Circulating nucleic acid (CNAS) and cancer-A survey. Biochim Biophys Acta 2007;1775:181-232.
7. Pinzani P, Salvianti F, Pazzagli M, Orlando C. Circulating nucleic acids in cancer and pregnancy. Methods 2010;50:302-7.
8. Jung K, Fleishhacker M, Rabien A. Cell-free DNA in the blood as a solid tumor biomarker-A critical appraisal of the literature. Clin Chim Acta 2010;411:1611-24.
9. Sifakis S, Zaravinos A, Maiz N, Spandidos DA, Nicolaides KH. First-trimester maternal plasma cell-free fetal DNA and preeclampsia. Am J Obstet Gynecol 2009;201:472e1-7.
10. Hahn S, Rusterholz C, Hösli I, Lapaire O. Cell-free nucleic acids as potential markers for preeclampsia. Placenta 2011;32:S17-20.
11. Sharma D, Trivedi SS, Bhattacharjee J. Intergenotypic variation of endothelial dysfunction and inflammatory markers in eclampsia. Hypertens Pregnancy 2013;32:11-9.
12. Devonshire AS, Whale AS, Gutteridge A, Jones G, Cowen S, Foy CA, et al. Towards standardization of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem 2014;406:6499-512.
13. van der Vaart M, Pretorius PJ. A method for characterization of total circulating DNA. Ann N Y Acad Sci 2008;1137:92-7.
14. Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C, et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 2003;21:3902-8.
15. Boni L, Casinotti E, Canziani M, Dionigi G, Rovera F, Dionigi R. Free circulating DNA as possible tumor marker in colorectal cancer. Surg Oncol 2007;16:S29-S31.
16. van der Vaart M, Pretorius JP. Is the role of circulating DNA as a biomarker of cancer being prematurely overrated? Clin Biochem 2010;43:26-36.
17. Muoliere F, Robert B, Peyrotte EA, Del Rio M, Ychou M, Molina F, et al. High fragmentation characterized tumour-derived circulating DNA. PlosOne 2011;6:e23418.
18. Frattini M, Balestra D, Verderio P, Gallino G, Leo E, Sozzi G, et al. Reproducibility of a semiquantitative measurement of circulating DNA in plasma from neoplastic patients. J Clin Oncol 2005;23:3163-4.
19. Koff JL, Ramachandiran S, Bernal-Mizrachi L. A time to kill: targeting apoptosis in cancer. Int J Mol Sci 2015;16:2942-55.
20. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61:1659-65.
21. Thierry AR, Mouliere F, Gongora C, Ollier J, Robert B, Ychou M, et al. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. NAR 2010;38:6159-75.
22. Mouliere F, El Messaoudi S, Pang D, Dritschilo A, Thierry AR. Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. Mol Oncol 2014;8:927-41.
23. Jung M, Klotzek S, Lewandowski M, Fleischhacker M, Jung K. Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin Chem 2003;49:1028-9.
24. El Messaoudi S, Rolet F, Mouliere F, Thierry AR. Circulating cell free DNA: preanalytical considerations. Clin Chim Acta 2013;424:222-30.
25. Pau CP, Wells SK, Granade TC. Protocol for the use of a rapid real-time PCR method for the detection of HIV-1 proviral DNA using double-stranded primer. Methods Mol Biol 2012;903:263-71.
26. Stebbing J, Bower M. Cell-free DNA as a biomarker in the context of cancer, viruses, and methylation. J Infect Dis 2012;205:1032-4.
27. Schwarzenbach H, Pantel K, Kemper B, Beeger C, Otterbach F, Kimmig R, et al. Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer. Breast Cancer Res 2009;11:R71.
28. Malentacchi F, Pazzagli M, Simi L, Orlando C, Wyrich R, Hartmann CC, et al. SPIDIA-DNA: an External Quality Assessment for the pre-analytical phase of blood samples used for DNAbased analyses. Clin Chim Acta 2013;424:274-86.
29. Pazzagli M, Malentacchi F, Simi L, Orlando C, Wyrich R, Günther K, et al. SPIDIA-RNA: first external quality assessment for the pre-analytical phase of blood samples used for RNA based analyses. Methods 2013;59:20-31.
30. Wong D, Moturi S, Angkachatchai V, Mueller R, DeSantis G, van den Boom D, et al. Optimizing blood collection, transport and storage conditions for cell free DNA increases access to prenatal testing. Clin Biochem 2013;36:1099-114.
31. Norton SE, Lechner JM, Williams T, Fernando MR. A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood storage and shipping as determined by digital PCR. Clin Biochem 2013;46:1561-5.